Panorama de portfólio de vacinas em desenvolvimento

Os dados são atualizados semanalmente, das seguintes fontes:

WHO – https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

London School of Hygiene & Tropical Medicine – https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker

Busque por termos

Selecione ao lado o filtro desejado:

Últimos 30 registros

Abaixo os últimos 30 registros encontrados em nossa base de dados.

Digite um termo acima para filtrar sua busca na tabela abaixo.

Candidato Patrocínio Fase de testes Instituição Data
Moderna COVID‑19 Vaccine (mRNA-1273). APROVADA - Andorra, Brazil, Canada, European Union, Faroe Islands, Greenland, Guatemala, Honduras, Iceland, India, Israel, Japan, Liechtenstein, Moldova, Mongolia, Norway, Palestine, Philippines, Qatar, Saint Vincent and the Grenadines, Singapore, South Korea, Switzerland, Taiwan, Thailand, United Kingdom, United States, Vietnam, WHOModernaPhase 3Kaiser Permanente Washington Health Research Institute2021/03/11
EpiVacCorona - APROVADA (Russia, Turkmenistan)Federal Budgetary Research Institution State Research Center of Virology and BiotechnologyPeptide vaccine Federal Budgetary Research Institution State Research Center of Virology and Biotechnology2021/03/11
No name announced. APROVADA - ChinaWuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)PHASE-3 - Inactivated vaccine Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)2021/03/11
COVID-19 Vaccine AstraZeneca (AZD1222); also known as Covishield - APROVADA -Argentina, Bahrain, Bangladesh, Barbados, Brazil, Canada, Chile, Dominican Republic, Ecuador, El Salvador, Egypt, EU, Guyana, Hungary, India, Iraq, Malaysia, Maldives, Mauritius, Mexico, Morocco, Myanmar, Nepal, Nigeria, Pakistan, Philippines, Saint Vincent and the Grenadines, South Africa, South Korea, Sri Lanka, Taiwan, Thailand, UK, VietnamBARDA, OWSPHASE 3 - AUTHORIZATION / APPROVAL. Afghanistan, Albania, Algeria, Andorra, Angola, Argentina, Australia, Bahamas, Bahrain, Bangladesh, Barbados, Bhutan, Bolivia, Botswana, Brazil, Brunei, Cabo Verde, Cambodia, Canada, Cambodia, Caribbean, Chile, Colombia, Congo, Costa Rica, Djibouti, Dominican Republic, Ecuador, El Salvador, Egypt, Eswatani, Ethiopia, European Union, Faroe Islands, Fiji, Gambia, Georgia, Ghana, Greenland, Guatemala, Guinea-Bissau, Guyana, Honduras, Hungary (SII), Iceland, India, Indonesia, Iran, Iraq, Ivory Coast, Japan, Jordan, Kenya, Kosovo, Kuwait, Lebanon, Lesotho, Liberia, Libya, Malawi, Malaysia, Maldives, Mali, Mauritius, Mexico, Moldova, Mongolia, Morocco, Myanmar, Namibia, Nepal, Nicaragua, Nigeria, North Macedonia, Norway, Oman, Pakistan, Palestine, Panama, Papua New Guinea, Peru, Philippines, Rwanda, Saint Vincent and the Grenadines, Samoa, Serbia, Seychelles, Sierra Leone, Somalia, South Korea, South Sudan, Sri Lanka, Sudan, Suriname, Taiwan, Tajikistan, Thailand, Timor Leste, Tonga, Togo, Tuvalu, Uganda, Ukraine, UK, Uzbekistan, Vietnam, WHO (Oxford; SII/SK), Yemen, Zambia AstraZeneca - UK2021/03/11
JNJ-78436735 (formerly Ad26.COV2.S). APROVADA - Bahrain, Saint Vincent and the Grenadines, USJanssen Vaccines (Johnson & Johnson)PHASE 3 - Non-replicating viral vector(Johnson & Johnson) / The Netherlands, US2021/03/11
Convidicea (Ad5-nCoV) / APROVADA (Mexico, China, Pakistan) CanSino BiologicsPHASE -3 - Recombinant vaccine (adenovirus type 5 vector)CanSino Biologics - CHINA2021/03/11
CoviVac - Aprovada - RússiaChumakov Federal Scientific Center for Research and Development of Immune and Biological ProductsInactivated vaccineChumakov Federal Scientific Center for Research and Development of Immune and Biological Products = Rússia2021/03/11
ZF2001 - APROVADA - Uzbekistan Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of SciencesRecombinant vaccineChina, Uzbekistan2021/03/11
Abdala (CIGB 66)Center for Genetic Engineering and Biotechnology Phase 3Center for Genetic Engineering and Biotechnology2021/03/11
VIR-7831Medicago; GSK; DynavaxPhase 2/3Medicago 2021/03/11
No name announcedImmunityBio; NantKwestPhase 2/3 - Adenovirus-based vaccine 2021/03/11
UB-612COVAXXPhase 2/3 - Multitope peptide-based vaccine United Biomedical Inc. (UBI) 2021/03/11
No name announcedSanofi; GlaxoSmithKlineRecombinant protein vaccine - Phase 2 Various2021/03/11
BNT162Pfizer, BioNTechPhase 1/2/3Multiple study sites in Europe, North America and China2021/03/11
Soberana 1 and 2Finlay Institute of VaccinesPhase 1/2/3Finlay Institute of Vaccines2021/03/11
AdCLD-CoV19Cellid; LG ChemPhase 1/2aKorea University Guro Hospital2021/03/11
NanocovaxNanogen BiopharmaceuticalPhase 1/2 - Recombinant vaccine (Spike protein)Military Medical Academy (Vietnam)2021/03/11
EuCorVac-19EuBiologicsPhase 1/2 - nanoparticle vaccineEunpyeong St. Mary’s Hospital2021/03/11
Mambisa (CIGB 669)Center for Genetic Engineering and BiotechnologyPhase 1/2 - Protein subunit vaccineCenter for Genetic Engineering and Biotechnology 2021/03/11
IIBR-100Israel Institute for Biological ResearchPhase 1/2 - Recombinant vesicular stomatitis virus (rVSV) vaccineHadassah Medical Center; Sheba Medical Center Hospital2021/03/11
No name announcedWest China Hospital, Sichuan UniversityPhase 1/2 - SF9 cell vaccine candidateWest China Hospital, Sichuan University2021/03/11
VLA2001Valneva; National Institute for Health Research (NIHR)Phase 1/2 - Inactivated vaccineMultiple NIHR testing sites2021/03/11
No name announcedCEPIPhase 1/2 - Adjuvanted protein subunit vaccine2021/03/11
ARCT-021 (LUNAR-COV19)Arcturus Therapeutics and Duke-NUS Medical SchoolPhase 1/2 - Self-replicating RNA vaccineDuke-NUS Medical School, Singapore2021/03/11
No name announcedChinese Academy of Medical Sciences, Institute of Medical BiologyPhase 1/2 - Inactivated vaccineWest China Second University Hospital, Yunnan Center for Disease Control and Prevention 2021/03/11
AV-COVID-19Aivita Biomedical, Inc.Phase 1b/2 - Dendritic cell vaccineRumah Sakit Umum Pusat Dr Kariadi2021/03/11
PTX-COVID19-BProvidence Therapeutics; Canadian governmentPhase 1 - mRNA-based vaccine 2021/03/11
COVI-VACCodagenix; Serum Institute of India Phase 1 - Intranasal vaccine2021/03/11
CORVax12OncoSec; Providence Cancer InstitutePhase 1 - DNA vaccine (plasmid)Providence Portland Medical Center2021/03/11
MVA-SARS-2-SUniversitätsklinikum Hamburg-Eppendorf; German Center for Infection Research; Philipps University Marburg Medical Center; Ludwig-Maximilians - University of Munich Phase 1 - Modified vaccinia virus ankara (MVA) vector vaccine candidateUniversity Medical Center Hamburg-Eppendorf2021/03/11
Acompanhe conosco os principais dados de covid do Brasil
https://covid.saude.gov.br/

Painel de casos de doença pelo coronavírus 2019 (COVID-19) no Brasil pelo Ministério da Saúde. Diariamente, o Ministério da Saúde, por meio da Secretaria de Vigilância em Saúde (SVS/MS) divulga dados consolidados sobre o COVID-19. Saiba mais sobre o painel.

https://bigdata-covid19.icict.fiocruz.br/

Este projeto utiliza recursos computacionais e cientistas de dados da Plataforma de Ciência de Dados aplicada à Saúde do Laboratório de Informação em Saúde do Icict da Fiocruz (PCDaS), hospedada no Laboratório Nacional de Computação Científica (LNCC).

Campus Sede:

Av. Brasil, 4365 – Manguinhos, Rio de Janeiro – CEP: 21040-900 – Tel: (0xx21) 2598-4242

Este portal é regido pela Política de Acesso Aberto ao Conhecimento, que busca garantir à sociedade o acesso gratuito, público e aberto ao conteúdo integral de toda obra intelectual produzida pela Fiocruz.

© COPYRIGHT / Todos os direitos reservados ao Laboratório de Informação Científica e Tecnológica em Saúde – LICTS / FIOCRUZ